세계의 나노의학 시장 평가 : 나노 분자 유형별, 용도별, 적응 질환별, 지역별, 기회 및 예측(2018-2032년)

Global Nanomedicine Market size was valued at USD 197.66 billion in 2024 which is expected to reach USD 375.17 billion in 2032 growing with a CAGR of 8.34% for the forecast period between 2025 and 2032.

Emerging new drug delivery technologies, the benefits of nanomedicine in numerous healthcare applications, and an increase in government support and financing are driving market expansion. Furthermore, the growing need for safe and cost-effective medicines contributes to market expansion.

Nanomedicine enhances the delivery of medicine by manipulating materials at the nanoscale. Therefore, nanomedicine has made it possible to treat a variety of diseases. As several products are in the development stage, nanomedicine is now in its infancy. The developing technologies for drug delivery are important elements that are anticipated to boost the growth of the nanomedicine market in the forecast period. However, the industry is projected to be hampered by the lengthy clearance procedure and the complications associated with the use of nanomedicines.

Advancement in Medical Technology

The invention of nanoscale medication delivery devices has been one of the most significant advances in nanomedicine. These methods employ nanoparticles to deliver medications directly to specific cells or tissues in the body, lowering the risk of adverse effects and increasing therapy efficacy. These drug delivery systems have the potential to transform the treatment of numerous illnesses, including cancer, diabetes, and cardiovascular disease.

Nanosensor is another significant milestone in nanomedicine which can detect and measure particular molecules or biomarkers in the body, offering vital diagnostic information for a variety of disorders. Nanosensors offer the potential to enhance early identification and treatment of numerous diseases by monitoring anything from blood glucose levels in diabetic patients to cancer indicators in cancer patients.

Rising Investments in Nanomedicine Facilities

Increasing investments in nanomedicine facilities are leading in enhanced research and development activities, resulting in the availability of innovative therapeutic solutions and drug delivery systems. The development of state-of-the-art facilities for nanomedicines allows for better experimentation, testing, and production of nanomedicines and supports the commercialization of novel products, making it for leading pharmaceutical companies to introduce advanced therapeutic solutions. Additionally, the company's capacity for developing nanomedicines also increases, allowing it to meet the growing demand from the healthcare industry.

For instance, in November 2024, Ardena Holding NV, one of the leading pharmaceutical contract development and manufacturing organization's received full Good Manufacturing Practice (GMP) approval for its nanomedicine facility in Oss, Netherlands. The company invested USD 20.6 million in the facility which includes state-of-the-art cleanrooms and advanced production spaces, reflecting the company's commitment to meeting stringent regulatory standards.

Increasing Awareness of Nanomedicines Among General Population

The worldwide nanomedicine market is primarily driven by rising healthcare awareness. People are more inclined to seek out medical treatment and services as they grow more conscious of the value of their health and wellness. With increased awareness of the potential benefits of nanomedicine, there has been a substantial surge in research and development activity in this sector. This has resulted in the creation of various innovative nanomedicine products and therapies, which are propelling the industry forward. Furthermore, the frequency of chronic illnesses including cancer, diabetes, and cardiovascular disorders is rising, which has increased demand for nanomedicine. Nanomedicine has emerged as a promising alternative for the treatment of various disorders due to its capacity to target certain cells and tissues in the body.

Government Initiatives

Government agencies are probably going to enhance their R&D spending, creating appealing chances for market development. Massive capital-intensive projects can be accelerated with the help of government funding. To improve nanoscale engineering, science, and technology, the National Science Foundation announced that it will spend a total of USD 84 million over the course of five years to re-establish the National Nanotechnology Coordinated Infrastructure. Additionally, the Canadian government funds research in the fields of nanomedicine and regenerative medicine at the Canadian Institutes of Health Research (CIHR) and the Canadian Space Agency (CSA). As a result, it will fuel the expansion of the nanomedicine sector in the upcoming years.

Innovations in Nanomedicine

It is projected that the development of innovative nanoscience-based treatments will be actively pursued by reputable pharmaceutical firms, which will have an impact on the market for nanomedicine. For instance, in May 2022, the Marble Centre for Cancer Nanomedicine, in association with Alloy Therapeutics, FUJIFILM Holdings America Corporation, Sanofi, and Danaher Corporation, introduced an affiliate programme.

The programme intends to promote industry-academia research partnerships to support ground-breaking breakthroughs in the nanomedicine sector. Additionally, the expansion of the nanomedicine sector is anticipated to be aided by breakthroughs in nanotechnology and its growing applications in preventative interventions, early illness detection, prevention of chronic as well as acute diseases, and prophylaxis of acute as well as chronic disorders.

Impact of COVID-19

The global market for nanomedicine has been significantly impacted by the COVID-19 pandemic. While the pandemic brought difficulties for the sector, it also offered chances for development and innovation.

The pandemic impacted the nanomedicine supply chain by creating delays and shortages. The pandemic expedited nanomedicine research and development efforts, with many firms and researchers shifting their emphasis to finding answers to the virus. Nanomedicine has been at the forefront of COVID-19 therapy development, such as the utilisation of nanoparticles for medication delivery and the creation of nanosensors for viral detection.

Key Players Landscape and Outlook

According to a study article titled "Recent Advances in Nanomaterials Development for Nanomedicine and Cancer" that was published in July 2021, Point-of-care and extremely sensitive techniques of cancer diagnosis have also been developed using a lot of nano-based materials and technologies. As a result, the market is expanding due to developments in nanomedicine for the diagnosis of cancer.

In January 2022, Pfizer and Acuitas Therapeutics announced their agreement for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Nanomedicine Market Outlook, 2018-2032F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Nanomolecule Type
  • 4.2.1. Nanoparticles
    • 4.2.1.1. Polymer-Based
    • 4.2.1.2. Lipid-Based
    • 4.2.1.3. Nanocrystals
    • 4.2.1.4. Inorganic
    • 4.2.1.5. Others
  • 4.2.2. Nanoshells
  • 4.2.3. Nanodevices
  • 4.2.4. Nanotubes
• 4.3. By Applications
  • 4.3.1. Drug Delivery
  • 4.3.2. Vaccines
  • 4.3.3. Diagnostic Imaging
  • 4.3.4. Regenerative Medicine
  • 4.3.5. Others
• 4.4. By Disease Indication
  • 4.4.1. Oncological Diseases
  • 4.4.2. Infectious Diseases
  • 4.4.3. Orthopedic Disorders
  • 4.4.4. Cardiovascular Diseases
  • 4.4.5. Others
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. South America
  • 4.5.4. Asia-Pacific
  • 4.5.5. Middle East & Africa
• 4.6. By Company Market Share (%), 2024

5. Global Nanomedicine Market Outlook, By Region, 2018-2032F

• 5.1. North America*
  • 5.1.1. By Nanomolecule Type
    • 5.1.1.1.1. Nanoparticles
      • 5.1.1.1.1.1. Polymer-Based
      • 5.1.1.1.1.2. Lipid-Based
      • 5.1.1.1.1.3. Nanocrystals
      • 5.1.1.1.1.4. Inorganic
      • 5.1.1.1.1.5. Others
    • 5.1.1.1.2. Nanoshells
    • 5.1.1.1.3. Nanodevices
    • 5.1.1.1.4. Nanotubes
  • 5.1.2. By Applications
    • 5.1.2.1.1. Drug Delivery
    • 5.1.2.1.2. Vaccines
    • 5.1.2.1.3. Diagnostic Imaging
    • 5.1.2.1.4. Regenerative Medicine
    • 5.1.2.1.5. Others
  • 5.1.3. By Disease Indication
    • 5.1.3.1.1. Oncological Diseases
    • 5.1.3.1.2. Infectious Diseases
    • 5.1.3.1.3. Orthopedic Disorders
    • 5.1.3.1.4. Cardiovascular Diseases
    • 5.1.3.1.5. Others
  • 5.1.4. By Region
    • 5.1.4.1.1. North America
    • 5.1.4.1.2. Europe
    • 5.1.4.1.3. South America
    • 5.1.4.1.4. Asia-Pacific
    • 5.1.4.1.5. Middle East & Africa
  • 5.1.5. United States*
    • 5.1.5.1. By Nanomolecule Type
      • 5.1.5.1.1. Nanoparticles
        • 5.1.5.1.1.1. Polymer-Based
        • 5.1.5.1.1.2. Lipid-Based
        • 5.1.5.1.1.3. Nanocrystals
        • 5.1.5.1.1.4. Inorganic
        • 5.1.5.1.1.5. Others
      • 5.1.5.1.2. Nanoshells
      • 5.1.5.1.3. Nanodevices
      • 5.1.5.1.4. Nanotubes
    • 5.1.5.2. By Applications
      • 5.1.5.2.1. Drug Delivery
      • 5.1.5.2.2. Vaccines
      • 5.1.5.2.3. Diagnostic Imaging
      • 5.1.5.2.4. Regenerative Medicine
      • 5.1.5.2.5. Others
    • 5.1.5.3. By Disease Indication
      • 5.1.5.3.1. Oncological Diseases
      • 5.1.5.3.2. Infectious Diseases
      • 5.1.5.3.3. Orthopedic Disorders
      • 5.1.5.3.4. Cardiovascular Diseases
      • 5.1.5.3.5. Others
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Denmark
  • 5.2.6. Turkey
  • 5.2.7. Spain
• 5.3. South America
  • 5.3.1. Brazil
  • 5.3.2. Argentina
  • 5.3.3. Colombia
• 5.4. Asia-Pacific
  • 5.4.1. India
  • 5.4.2. China
  • 5.4.3. Japan
  • 5.4.4. Australia
  • 5.4.5. Vietnam
  • 5.4.6. South Korea
  • 5.4.7. Malaysia
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa
  • 5.5.4. Israel
  • 5.5.5. Kuwait

6. Market Mapping, 2024

• 6.1. By Nanomolecule Type
• 6.2. By Application
• 6.3. By Disease Indication
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis - Volume and Value
• 7.3. Supply/Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges, Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. FDA Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2024)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)

11. Case Studies

12. Key Players Outlook

• 12.1. Pfizer Inc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Sanofi S.A.
• 12.3. Amgen Inc
• 12.4. Moderna, Inc
• 12.5. Novo Nordisk A/S
• 12.6. Celgene Corporation
• 12.7. Teva
• 12.8. Pharmaceutical Industries Ltd.
• 12.9. Abbott Laboratories
• 12.10. Johnson & Johnson Services, Inc.
• 12.11. Merck & Co., Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us & Disclaimer